These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16128199)

  • 21. Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: opportunities for multidisciplinary interventions.
    Teschemaker A; Lee E; Xue Z; Wutoh AK
    Am J Geriatr Pharmacother; 2008 Dec; 6(5):240-8. PubMed ID: 19161926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A once-a-year intravenous treatment of osteoporosis in postmenopausal women: implications for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2008; 22(4):169-71. PubMed ID: 18596484
    [No Abstract]   [Full Text] [Related]  

  • 23. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults.
    Richards JB; Cherkas LF; Spector TD
    Curr Med Res Opin; 2007 Feb; 23(2):293-9. PubMed ID: 17288683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
    Curtis JR; Westfall AO; Allison J; Freeman A; Kovac SH; Saag KG
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):710-8. PubMed ID: 16498575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National patterns of calcium use in osteoporosis in the United States.
    Stafford RS; Drieling RL; Johns R; Ma J
    J Reprod Med; 2005 Nov; 50(11 Suppl):885-90. PubMed ID: 16422278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
    Payer J; Killinger Z; Sulková I; Celec P
    Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brief supported lifestyle counseling: modest interventions yield modest effects.
    McManus DD; Ockene IS
    Arch Intern Med; 2008 Jan; 168(2):129-30. PubMed ID: 18227355
    [No Abstract]   [Full Text] [Related]  

  • 29. [Guideline stipulated treatment with calcium and vitamin D. Not even every third osteoporosis patient receives them].
    Fischer M
    MMW Fortschr Med; 2006 Jun; 148(22):50. PubMed ID: 16821582
    [No Abstract]   [Full Text] [Related]  

  • 30. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compliance with treatment in osteoporosis patients--an ongoing problem.
    Sambrook P
    Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidisciplinary patient education in groups increases knowledge on osteoporosis: a randomized controlled trial.
    Nielsen D; Ryg J; Nissen N; Nielsen W; Knold B; Brixen K
    Scand J Public Health; 2008 Jun; 36(4):346-52. PubMed ID: 18539688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventions to improve inpatient osteoporosis management following first osteoporotic fracture: the PREVENT project.
    Carpintero P; Gil-Garay E; Hernández-Vaquero D; Ferrer H; Munuera L
    Arch Orthop Trauma Surg; 2009 Feb; 129(2):245-50. PubMed ID: 19125257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
    Voskaridou E; Christoulas D; Konstantinidou M; Tsiftsakis E; Alexakos P; Terpos E
    Haematologica; 2008 Oct; 93(10):1588-90. PubMed ID: 18698086
    [No Abstract]   [Full Text] [Related]  

  • 35. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
    Jones TJ; Petrella RJ; Crilly R
    J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and management of osteoporosis in liver disease.
    Hay JE; Guichelaar MM
    Clin Liver Dis; 2005 Nov; 9(4):747-66, viii. PubMed ID: 16207574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consequences of poor compliance with bisphosphonates.
    Briesacher BA; Andrade SE; Yood RA; Kahler KH
    Bone; 2007 Nov; 41(5):882-7. PubMed ID: 17707710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].
    Bartl R; Götte S; Hadji P; Hammerschmidt T
    Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence and persistence: impact on outcomes and health care resources.
    Reginster JY
    Bone; 2006 Feb; 38(2 Suppl 2):S18-21. PubMed ID: 16443406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.